{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inflammatory+Myositis", "query": { "condition": "Inflammatory Myositis" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 61, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inflammatory+Myositis&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T22:14:56.054Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06152172", "title": "CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Idiopathic Inflammatory Myopathies", "Diffuse Cutaneous Systemic Sclerosis", "SLE Nephritis", "ANCA Associated Vasculitis" ], "interventions": [ { "name": "KYV-101", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Porter", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-08-05", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-02-18", "last_synced_at": "2026-06-10T22:14:56.054Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06152172" }, { "nct_id": "NCT03267277", "title": "Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Dermatomyositis", "Idiopathic Inflammatory Myopathies" ], "interventions": [ { "name": "Sodium Thiosulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Environmental Health Sciences (NIEHS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 15, "start_date": "2017-10-05", "completion_date": "2023-11-09", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-06-10T22:14:56.054Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03267277" }, { "nct_id": "NCT05869955", "title": "A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus", "Idiopathic Inflammatory Myopathy", "Systemic Sclerosis", "Rheumatoid Arthritis" ], "interventions": [ { "name": "CC-97540", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2023-09-13", "completion_date": "2028-08-29", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-10T22:14:56.054Z", "location_count": 30, "location_summary": "Aurora, Colorado • Denver, Colorado • New Haven, Connecticut + 19 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05869955" }, { "nct_id": "NCT07085104", "title": "A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus (With and Without Nephritis)", "Idiopathic Inflammatory Myopathy", "Systemic Sclerosis" ], "interventions": [ { "name": "ALLO-329", "type": "GENETIC" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Allogene Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 66, "start_date": "2025-11-13", "completion_date": "2032-10", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-06-10T22:14:56.054Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT07085104" }, { "nct_id": "NCT01148810", "title": "Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polymyositis", "Dermatomyositis" ], "interventions": [ { "name": "BAF312", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 18, "start_date": "2010-06-15", "completion_date": "2012-06-13", "has_results": true, "last_update_posted_date": "2019-04-25", "last_synced_at": "2026-06-10T22:14:56.054Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01148810" }, { "nct_id": "NCT02422875", "title": "Comparative Autoantibody and Immunologic Cell Marker Study", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Autoimmune Diseases", "Lupus Erythematosus, Systemic", "Communicable Diseases" ], "interventions": [], "intervention_types": [], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2500, "start_date": "2012-08", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-06-10T22:14:56.054Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02422875" }, { "nct_id": "NCT06698796", "title": "A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatomyositis", "Polymyositis" ], "interventions": [ { "name": "Dazukibart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 211, "start_date": "2025-01-22", "completion_date": "2027-11-25", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-10T22:14:56.054Z", "location_count": 4, "location_summary": "Glendale, Arizona • Allen, Texas • Houston, Texas + 1 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Allen", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Beckley", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06698796" }, { "nct_id": "NCT05523167", "title": "A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Active Idiopathic Inflammatory Myopathy", "Myositis", "Dermatomyositis", "Polymyositis", "Immune-Mediated Necrotizing Myopathy", "Antisynthetase Syndrome" ], "interventions": [ { "name": "EFG PH20 SC", "type": "BIOLOGICAL" }, { "name": "PBO", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2022-10-12", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2025-07-23", "last_synced_at": "2026-06-10T22:14:56.054Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05523167" }, { "nct_id": "NCT06308978", "title": "A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)", "Idiopathic Inflammatory Myositis (IIM)", "Systemic Sclerosis (SSc)", "Systemic Lupus Erythematosus (SLE)", "Lupus Nephritis" ], "interventions": [ { "name": "FT819", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "12 Years to 70 Years" }, "enrollment_count": 244, "start_date": "2024-03-28", "completion_date": "2042-09-30", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-10T22:14:56.054Z", "location_count": 16, "location_summary": "Beverly Hills, California • Fullerton, California • Irvine, California + 13 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06308978" }, { "nct_id": "NCT00278564", "title": "Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "MYOPATHY" ], "interventions": [ { "name": "Hematopoietic stem cell transplantation", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "ATG(rabbit)", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Rituxan", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": 7, "start_date": "2005-09", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2018-08-06", "last_synced_at": "2026-06-10T22:14:56.054Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00278564" } ] }